Evidence map›Paper›PMID 32238406›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2020

Prediagnostic 25-Hydroxyvitamin D Concentrations in Relation to Tumor Molecular Alterations and Risk of Breast Cancer Recurrence.

Cheng Peng, Yujing J Heng, Donghao Lu, Natalie C DuPre, Kevin H Kensler, Kimberly Glass, Oana A Zeleznik, Peter Kraft, David Feldman, Susan E Hankinson and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. The Breast Tumor Immune Microenvironment of DNA Double-Strand Break Repair Pathogenic Variant Carriers Is Enriched with Tumor-Associated Macrophages.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Cheng PengChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts. recpe@channing.harvard.edu.
Yujing J HengDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-8930-817X
Donghao LuChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0002-4186-8661
Natalie C DuPreDepartment of Epidemiology, University of Louisville School of Public Health and Information Science, Louisville, Kentucky.ORCID 0000-0003-4587-0467
Kevin H KenslerDivision of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
Kimberly GlassChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Oana A ZeleznikChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0002-8705-1163
Peter KraftDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
David FeldmanDepartment of Medicine, Stanford University School of Medicine, Stanford, California.
Susan E HankinsonDepartment of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts Amherst, Amherst, Massachusetts.
Kathryn RexrodeDivision of Women's Health, Harvard Medical School, Boston, Massachusetts.
A Heather EliassenChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Rulla M TamimiChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0003-2306-8668
Brigham and Women's Hospital · USHarvard University · USBeth Israel Deaconess Medical Center · USDana-Farber Cancer Institute · USStanford University · USUniversity of Louisville · USUniversity of Massachusetts Amherst · US

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8M
Life Course Cancer Epidemiology Cohort in WomenU01CA176726 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 2018 to 2025
$22.4M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Training Program in Cancer EpidemiologyT32CA009001 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI A. Heather Eliassen, Meir Stampfer · 1985 to 2026
$17.3M
Life Course Cancer Epidemiology Cohort in WomenUM1CA176726 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2013 to 2017
$15.7M
Epidemiologic StudiesU19CA148065 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI AHSAN, HABIBUL, BRUGGE, JOAN SIEFERT · 2010 to 2014
$10.6M
The Effects of Vitamin D on Mammographic Density and Breast TissueR01CA178263 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI REXRODE, KATHRYN M, TAMIMI, RULLA M · 2014 to 2018
$2.7M
Assessing the role of androgens in breast cancer riskR01CA166666 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI HANKINSON, SUSAN E · 2012 to 2015
$1.7M
Contributions of tumor molecular subtypes to prostate cancer racial disparitiesK99CA245900 · NCI · DANA-FARBER CANCER INST · PI KENSLER, KEVIN HUGHES · 2020 to 2021
$163k
NCI NIH HHS K99 CA245900NCI NIH HHS P01 CA087969NCI NIH HHS R01 CA166666NCI NIH HHS R01 CA178263NCI NIH HHS T32 CA009001NCI NIH HHS U01 CA176726NCI NIH HHS U19 CA148065NCI NIH HHS UM1 CA176726NCI NIH HHS UM1 CA186107
6 · The paper itself

Abstract

backgroundAlthough vitamin D inhibits breast tumor growth in experimental settings, the findings from population-based studies remain inconclusive. Our goals were to investigate the association between prediagnostic plasma 25-hydroxyvitamin D [25(OH)D] concentration and breast cancer recurrence in prospective epidemiologic studies and to explore the molecular underpinnings linking 25(OH)D to slower progression of breast cancer in the Nurses' Health Studies (NHS,

methodsPlasma 25(OH)D was measured with a high-affinity protein-binding assay and a radioimmunoassay. We profiled transcriptome-wide gene expression in breast tumors using microarrays. Hazard ratios (HR) of breast cancer recurrence were estimated from covariate-adjusted Cox regressions. We examined differential gene expression in association with 25(OH)D and employed pathway analysis. We derived a gene expression score for 25(OH)D, and assessed associations between the score and cancer recurrence.

resultsAlthough 25(OH)D was not associated with breast cancer recurrence overall [HR = 0.97; 95% confidence interval (CI), 0.88-1.08], the association varied by estrogen-receptor (ER) status (

conclusionsOur findings support an intriguing line of research for studies to better understand the mechanisms underlying the role of vitamin D in breast tumor progression, particularly for the ER-positive subtype. IMPACT: Vitamin D may present a personal-level secondary-prevention strategy for ER-positive breast cancer.

Indexed as

Breast NeoplasmsFemaleHumansMiddle AgedNeoplasm Recurrence, LocalProspective StudiesRisk FactorsVitamin D25-hydroxyvitamin DVitamin D

Identifiers

PMID32238406
PMCPMC7284927
OpenAlexW3014342868

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.